Key Highlights

  • Vertex Pharmaceuticals (NASDAQ:VRTX) reports third quarter 2026 results after the close on November 2, 2026; published consensus is non-GAAP EPS of USD 4.92 on Revenue near USD 3.4 billion.
  • Second quarter revenue was USD 3.33 billion, up 12 percent, with non-GAAP EPS of USD 4.73 and cash and marketable securities of USD 13.6 billion at June 30, 2026.
  • Full-year 2026 revenue guidance was raised to USD 13.1 billion to USD 13.2 billion from USD 12.95 billion to USD 13.1 billion, excluding the pending Acquisition of Crinetics (NASDAQ:CRNX).
  • Alyftrek sales reached USD 573.6 million versus USD 156.8 million a year earlier, while Journavx sales were USD 49.6 million, up 71 percent from the prior quarter.

What Vertex Reports After the Close

Vertex Pharmaceuticals (NASDAQ:VRTX) is scheduled to report on November 2, 2026 after the market close. Published estimates call for non-GAAP EPS of USD 4.92 and revenue of about USD 3.4 billion, roughly 2.1 percent above second quarter revenue of USD 3.33 billion, simple arithmetic on two published numbers. Cystic fibrosis revenue was USD 3.21 billion in the second quarter, up about 11 percent, and Trikafta and Kaftrio contributed USD 2.50 billion of it. The company lifted its full-year range at the second quarter release, a move that raised the bar for the third quarter print.

New Products Are the Growth Test

Vertex earns most of its revenue from cystic fibrosis medicines, so growth beyond that base depends on launches. Alyftrek, its newer cystic fibrosis treatment, grew from USD 156.8 million to USD 573.6 million year over year. Casgevy, a gene-edited therapy for blood disorders, brought in USD 76.4 million, up 151 percent from a year earlier and 78 percent from the prior quarter. Journavx, a non-opioid pain medicine, earned USD 49.6 million versus USD 12.0 million a year earlier. Analysts will look for continued sequential growth, because launches this small against USD 3.33 billion of quarterly revenue do not yet change the Earnings base.

Pipeline Dates and Risks

The FDA target action date for povetacicept in IgA nephropathy is November 30, 2026, the nearest binary event after the report. Vertex expects to complete enrollment of both Phase 3 studies of suzetrigine in diabetic peripheral neuropathy by the end of 2026, and it plans updated timelines for zimislecel in type 1 diabetes and VX-017 later this year. Risks include dependence on one franchise, regulatory delays, uneven launches and acquisition integration. Macro risk is also elevated: the S&P 500 fell 1.8 percent on October 30, 2026, and the Nasdaq Composite lost 2.9 percent, according to published market data.

Where Things Stand

The biotech is Vertex Pharmaceuticals (NASDAQ:VRTX), which lifted 2026 revenue guidance to USD 13.1 billion to USD 13.2 billion and faces an FDA decision on povetacicept on November 30. Consensus of USD 4.92 in EPS and about USD 3.4 billion in revenue looks achievable against the second quarter run rate. The balance of evidence favors a steady cystic fibrosis base with small but fast-growing launches, offset by pipeline binary risk. The Earnings Call and the FDA date are the next catalysts.